$198.88
2.08%
Indicators
| Indicator | Value | Meaning |
|---|---|---|
| Quality rank | 97.7 | Cross-sectional percentile built by the pipeline |
| RSI 14 | 76.1 | Relative strength index over 14 days |
| SMA 20 | 155.69 | 20-day simple moving average |
| SMA 50 | 110.11 | 50-day simple moving average |
| EMA 20 | 157.08 | 20-day exponential moving average |
| ATR 14 | 12.84 | Average true range over 14 days |
| RVOL 20 | 0.87 | Volume relative to its own 20-day average |
Values are read from the stored feature table as of 2026-09-25, source yahoo. A dash means the pipeline has no value for that indicator; it is not replaced by an estimate.
Detected patterns
Gap down
2026-09-22
BEARISHStrength 26%
Volatility breakout
2026-09-21
BULLISHStrength 100%
Gap up
2026-09-21
BULLISHStrength 46%
Gap up
2026-09-17
BULLISHStrength 47%
Gap up
2026-09-04
BULLISHStrength 32%
Gap down
2026-09-03
BEARISHStrength 32%
A pattern is a description of stored prices, not a prediction. Crosses need more than 200 bars, so an instrument with a short history shows fewer of them.
Related news
Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks
In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...
Yahoo2026-09-26Sentiment —
Moderna (MRNA) Held Investment Talks With The UAE Government
Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing and R&D collaboration. The discussions focus on expanded research capabilities, potential local production, and broader access to Middle Eastern healthcare markets. Management framed the UAE engagement as part of a wider push to build out Moderna's international footprint beyond existing Western partnerships. The UAE collaboration talks matter, but investors also need...
Yahoo2026-09-26Sentiment —
U.S. stocks advanced for the week while Treasury yields surged and petroleum markets remained in focus. Read more about this week's major events on Wall Street.
SeekingAlpha2026-09-26Sentiment —
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA) concluded the recent trading session at $198.88, signifying a +2.08% move from its prior day's close.
Yahoo2026-09-25Sentiment —
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?
Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.
Yahoo2026-09-25Sentiment —
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.
Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.
Yahoo2026-09-25Sentiment —
Moderna Stock Reached New 52-Week High: What's Happening?
Moderna Inc. (NASDAQ: MRNA) shares are trading higher Friday, hitting a fresh 52-week high on anticipation of clinical trial data.
Benzinga2026-09-25Sentiment —
Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.
Key TakeawaysOncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.
Yahoo2026-09-25Sentiment —